Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M60,654Revenue $M100,887Net Margin (%)2.2Altman Z-Score3.4
Enterprise Value $M76,675EPS $2.6Operating Margin %3.8Piotroski F-Score7
P/E(ttm)29.5Beneish M-Score-2.5Pre-tax Margin (%)3.3Higher ROA y-yY
Price/Book3.910-y EBITDA Growth Rate %24.4Quick Ratio0.5Cash flow > EarningsY
Price/Sales0.65-y EBITDA Growth Rate %20.7Current Ratio0.6Lower Leverage y-yN
Price/Free Cash Flow15.5y-y EBITDA Growth Rate %17.2ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %--PEG1.4ROE % (ttm)11.4Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M676ROIC % (ttm)7.9Gross Margin Increase y-yY

Gurus Latest Trades with ESRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ESRXVanguard Health Care Fund 2015-06-30 Reduce-0.56%$83.85 - $91.18
($87.35)
$ 90.253%Reduce 95.26%151,900
ESRXKen Fisher 2015-06-30 Reduce$83.85 - $91.18
($87.35)
$ 90.253%Reduce 0.11%533,442
ESRXGlenn Greenberg 2015-03-31 Reduce-1.76%$80.71 - $87.62
($83.87)
$ 90.258%Reduce 14.51%3,495,539
ESRXWallace Weitz 2015-03-31 Reduce-0.61%$80.71 - $87.62
($83.87)
$ 90.258%Reduce 15.15%1,429,702
ESRXDodge & Cox 2015-03-31 Add0.4%$80.71 - $87.62
($83.87)
$ 90.258%Add 25.83%24,221,504
ESRXJoel Greenblatt 2015-03-31 Add0.31%$80.71 - $87.62
($83.87)
$ 90.258%Add 1814.84%493,798
ESRXHOTCHKIS & WILEY 2015-03-31 Add0.11%$80.71 - $87.62
($83.87)
$ 90.258%Add 21.31%2,003,400
ESRXCharles Brandes 2015-03-31 Reduce-0.07%$80.71 - $87.62
($83.87)
$ 90.258%Reduce 2.63%2,149,660
ESRXChris Davis 2015-03-31 Add0.06%$80.71 - $87.62
($83.87)
$ 90.258%Add 1.61%13,212,411
ESRXJohn Keeley 2015-03-31 Reduce$80.71 - $87.62
($83.87)
$ 90.258%Reduce 1.74%30,458
ESRXMario Gabelli 2015-03-31 Reduce$80.71 - $87.62
($83.87)
$ 90.258%Reduce 3.41%130,279
ESRXKen Fisher 2015-03-31 Add$80.71 - $87.62
($83.87)
$ 90.258%Add 0.99%534,029
ESRXGlenn Greenberg 2014-12-31 Reduce-2.33%$69.65 - $85.96
($78.34)
$ 90.2515%Reduce 17.94%4,088,652
ESRXChris Davis 2014-12-31 Add0.65%$69.65 - $85.96
($78.12)
$ 90.2516%Add 22.09%13,002,699
ESRXWallace Weitz 2014-12-31 Reduce-0.19%$69.65 - $85.96
($78.12)
$ 90.2516%Reduce 5.17%1,684,987
ESRXVanguard Health Care Fund 2014-12-31 Reduce-0.07%$69.65 - $85.96
($78.26)
$ 90.2515%Reduce 11.45%3,206,500
ESRXDodge & Cox 2014-12-31 Add0.06%$69.65 - $85.96
($78.26)
$ 90.2515%Add 4.22%19,248,979
ESRXHOTCHKIS & WILEY 2014-12-31 Reduce-0.05%$69.65 - $85.96
($78.26)
$ 90.2515%Reduce 10.80%1,651,500
ESRXMario Gabelli 2014-12-31 Reduce-0.04%$69.65 - $85.96
($78.12)
$ 90.2516%Reduce 45.53%134,879
ESRXCharles Brandes 2014-12-31 Reduce-0.04%$69.65 - $85.96
($78.26)
$ 90.2515%Reduce 2.05%2,207,728
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ESRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ESRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Wimberly GarySr. VP & Ch. Information Off. 2015-06-09Sell1,644$87.143.01view
Wimberly GarySr. VP & Ch. Information Off. 2015-06-01Sell46,069$86.154.19view
STERNBERG SEYMOURDirector 2015-05-27Sell6,870$90.23-0.52view
MYERS WOODROW A JRDirector 2015-05-08Sell14,342$85.325.2view
BENANAV GARY GDirector 2015-05-04Sell10,000$87.392.71view
Wade Sara ESr. VP, Ch. Human Res. Off. 2015-05-01Sell12,000$86.533.73view
Norton David ASVP, Specialty & Supply Chain 2015-05-01Sell12,029$86.533.73view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-03-02Sell2,674$84.396.36view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-02-25Sell27,603$87.552.52view
Ebling Keith J.Exec. VP and General Counsel 2014-12-02Sell10,000$84.256.54view

Quarterly/Annual Reports about ESRX:

News about ESRX:

Articles On GuruFocus.com
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
David Rolfe Adds to Most Valuable Stakes in His Portfolio Jun 18 2015 
Dodge & Cox Keeps Buying Express Scripts May 27 2015 
Chris Davis Adds to his Express Scripts Position May 15 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
20 Questions With David Rolfe May 08 2015 
Analyzing Chris Davis' Top Holdings Apr 14 2015 
Charles Brandes' Top Growth Stocks Apr 07 2015 
CVS Health Corporation (CVS) Dividend Stock Analysis Apr 07 2015 
UnitedHealth Group Is Ready For A Huge Pharmacy Deal Apr 06 2015 

More From Other Websites
How Express Scripts Makes Money Jul 29 2015
Express Scripts says costly new cholesterol drugs could 'wreak havoc' Jul 29 2015
DoD awards medical records contract to Cerner, Leidos & A... Jul 29 2015
Edited Transcript of ESRX earnings conference call or presentation 29-Jul-15 12:30pm GMT Jul 29 2015
Express Scripts (ESRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 29 2015
Dow adds 100 points as Street awaits Fed statement; earnings eyed Jul 29 2015
Express Scripts says costly new cholesterol drugs could wreak havoc Jul 29 2015
Express Scripts (ESRX) Tops Q2 Earnings, Ups 2015 View - Analyst Blog Jul 29 2015
Express Scripts Holding Co Earnings Call scheduled for 8:30 am ET today Jul 29 2015
Early movers: HLT, ANTM, ETN, TWTR, GSK & more Jul 29 2015
Express Scripts Raises Guidance as Earnings Top Views Jul 28 2015
Express Scripts tops 2Q profit forecasts Jul 28 2015
Express Scripts tops 2Q profit forecasts Jul 28 2015
Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range Jul 28 2015
Express Scripts (ESRX) Stock Gains in After-Hours Trading on Earnings Beat Jul 28 2015
EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 28 2015
Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range Jul 28 2015
Top trades for the 2nd half: ESRX, MA & GILD Jul 28 2015
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and... Jul 28 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Srichardson
ReplySrichardson - 11 months ago
How do you see the % of Total Asset for a position in a guru portfolio?
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK